Amedisys Inc. (NASDAQ:AMED) shares dropped 1.5% on Tuesday . The company traded as low as $47.01 and last traded at $47.05, with a volume of 82,763 shares changing hands. The stock had previously closed at $47.79.

AMED has been the subject of a number of recent analyst reports. Stephens initiated coverage on shares of Amedisys in a report on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 price objective for the company. Mizuho downgraded shares of Amedisys from a “buy” rating to a “neutral” rating and cut their target price for the stock from $57.00 to $55.00 in a research note on Wednesday, August 3rd. Zacks Investment Research raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $57.00 target price on the stock in a research note on Monday, May 9th. Jefferies Group reaffirmed a “buy” rating and set a $59.00 target price on shares of Amedisys in a research note on Wednesday, May 25th. Finally, Royal Bank Of Canada upped their target price on shares of Amedisys from $41.00 to $48.00 and gave the stock a “sector perform” rating in a research note on Friday, May 6th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $51.75.

The stock’s 50-day moving average is $51.05 and its 200 day moving average is $47.70. The company has a market capitalization of $1.60 billion and a price-to-earnings ratio of 41.84.

Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, August 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42. The company earned $360 million during the quarter, compared to analyst estimates of $353.07 million. During the same period in the prior year, the business posted $0.43 earnings per share. Amedisys’s revenue was up 14.8% on a year-over-year basis. On average, equities analysts expect that Amedisys Inc. will post $1.69 earnings per share for the current year.

Several large investors recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its stake in Amedisys by 5.3% in the fourth quarter. Rhumbline Advisers now owns 37,499 shares of the company’s stock valued at $1,474,000 after buying an additional 1,875 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Amedisys by 32.4% in the fourth quarter. New York State Common Retirement Fund now owns 91,345 shares of the company’s stock valued at $3,592,000 after buying an additional 22,365 shares in the last quarter. Morgan Stanley boosted its stake in Amedisys by 21.1% in the fourth quarter. Morgan Stanley now owns 330,210 shares of the company’s stock valued at $12,983,000 after buying an additional 57,461 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in Amedisys by 230.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 31,100 shares of the company’s stock valued at $1,223,000 after buying an additional 21,700 shares in the last quarter. Finally, Trexquant Investment LP bought a new stake in Amedisys during the fourth quarter valued at about $1,031,000.

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.